Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1643 1645
This examiner grants 45% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17916942 | VACCINE PLATFORM FOR THE INDUCTION OF SYSTEMIC IMMUNE RESPONSES | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18271579 | COMBINATION THERAPY USING AN ANTI-FUCOSYL-GM1 ANTIBODY | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 18632737 | NKG2D-FC FOR IMMUNOTHERAPY | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 18003999 | METHODS FOR PREDICTING THE RISK OF RECURRENCE AND/OR DEATH OF PATIENTS SUFFERING FROM A SOLID CANCER AFTER PREOPERATIVE ADJUVANT THERAPY AND RADICAL SURGERY | Non-Final OA | Université Paris Cité |
| 16640942 | METHODS FOR MODULATING THE INTERACTION BETWEEN EWS-FLI1 AND BAF COMPLEXES | Non-Final OA | The General Hospital Corporation |
| 17615410 | TUMOR CELL-DERIVED EXOSOMES AND THEIR APPLICATIONS | Final Rejection | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18312719 | SYSTEMS AND METHODS FOR PROMOTING REMYELINATION WITH FACTORS DERIVED FROM UMBILICAL CORD BLOOD MACROPHAGES | Non-Final OA | Duke University |
| 18356417 | GENETIC VARIATIONS ASSOCIATED WITH BENIGN PAROXYSMAL POSITIONAL VERTIGO | Non-Final OA | Father Flanagan's Boys' Home Doing Business as Boys Town National Research Hospital |
| 17924975 | METHODS, THERAPIES AND USES FOR TREATING CANCER | Final Rejection | PFIZER INC. |
| 18469844 | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY | Non-Final OA | Gilead Sciences, Inc. |
| 18734619 | LIPOSOME ENCAPSULATED AFFINITY DRUG | Final Rejection | L.E.A.F. HOLDINGS GROUP LLC |
| 18046300 | PD-1 SIGNAL INHIBITOR COMBINATION THERAPY | Final Rejection | KYOTO UNIVERSITY |
| 18413155 | DIAGNOSTIC METHODS FOR LIVER DISORDERS | Final Rejection | Meso Scale Technologies, LLC. |
| 17625226 | Intratumoral TFR Cells Curtail Anti-PD-1 Treatment Efficacy | Non-Final OA | UNIVERSITY OF SOUTHAMPTON |
| 18309985 | TIMP1 AS A MARKER FOR CHOLANGIOCARCINOMA | Non-Final OA | Roche Diagnostics Operations, Inc. |
| 18645607 | Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious Diseases | Non-Final OA | OSE Immunotherapeutics |
| 18578142 | Xenon Gas for Use in the Treatment of Gliomas | Non-Final OA | Universität Heidelberg |
| 18262236 | Methods of Cancer Treatment Using Anti-TIGIT Antibodies in Combination with Anti-PD1 Antibodies | Non-Final OA | Beigene Switzerland GMBH |
| 17079326 | CLAUDIN-18 AS A DIAGNOSTIC AND THERAPEUTIC CANCER TARGET | Non-Final OA | ASTELLAS PHARMA INC. |
| 17055722 | Urinary DNA Detection For Urothelial Cancer | Final Rejection | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center |
| 16310566 | Active Alpha-5-Beta-1 Integrin As A Biomarker For Enhancing Tumor Treatment Efficacy | Final Rejection | Institute For Cancer Research d/b/a The Research Institute Of Fox Chase Cancer Center |
| 17622225 | COMBINATION CANCER IMMUNOTHERAPY | Final Rejection | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. |
| 18347295 | ANTIBODIES TARGETED TO CD147 | Non-Final OA | Ibex Biosciences, Inc. |
| 17928048 | TREATMENT OF CANCER | Final Rejection | Immutep S.A.S. |
| 18075391 | METHODS FOR TREATING COLORECTAL AND METASTATIC COLORECTAL CANCERS | Final Rejection | Isofol Medical AB |
| 18041723 | HUMANIZED ANTIBODY, CHIMERIC ANTIGEN RECEPTOR, NUCLEIC ACID, VECTOR, CELL AND USE | Non-Final OA | SHENZHEN IMMUNOFOCO BIOTECHNOLOGY CO.,LTD. |
| 18020752 | METASTATIC BIOMARKER | Final Rejection | OXFORD BROOKES UNIVERSITY |
| 18165683 | METHODS OF DETECTING AND TREATING IMMUNOTHERAPY-RESISTANT CANCER | Non-Final OA | University of Augsburg |
| 18016901 | PANCREATIC CANCER DIAGNOSTIC COMPOSITION TO BE USED IN BUFFY COAT SAMPLE | Final Rejection | HuVet bio, Inc. |
| 18005568 | USE OF ANTIGEN COMBINATION FOR DETECTING AUTOANTIBODIES IN LUNG CANCER | Non-Final OA | ONCIMMUNE LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy